BiotechTube

SHR7280 tablets

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

Conditions

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

Trial Timeline

Mar 6, 2022 → Aug 3, 2023

NCT ID
NCT05082233

About SHR7280 tablets

SHR7280 tablets is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Female Subjects Undergoing COH in ART to Prevent Early Ovulation. The current trial status is completed. This product is registered under clinical trial identifier NCT05082233. Target conditions include Female Subjects Undergoing COH in ART to Prevent Early Ovulation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06949124Phase 1Completed
NCT05082233Phase 2Completed

Competing Products

20 competing products in Female Subjects Undergoing COH in ART to Prevent Early Ovulation

See all competitors
ProductCompanyStageHype Score
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
77
ASP3325 + PlaceboAstellas PharmaPhase 1
33
EnsitrelvirShionogiPhase 1
33
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
85
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
77
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
77
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
33
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
77
SHR3162Jiangsu Hengrui MedicinePhase 1
33
AZD3293 + PlaceboAstraZenecaPhase 1
33
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
77
AZD2516 + PlaceboAstraZenecaPhase 1
33
Durvalumab + TremelimumabAstraZenecaPhase 2
52
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
33
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
52
Zibotentan + EE/LNGAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85